SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of the Q3 report is drawing attention, with traders focused on BRIUMVIs sales growth and possible guidance updates. Buyout and short-squeeze theories are circulating but remain speculation; the upcoming subcutaneous BRIUMVI data is another anticipated catalyst, while some traders warn the rally may already reflect high expectations.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Berkshires disclosed accumulation of a large Lennar stake has fueled bargain-buying interest, but traders are debating it against Hunterbrooks short-report allegations about Lennars transactions with spinoff Millrose. The dispute adds to concerns over weak results and outlook, pressured affordability, and elevated mortgage rates.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is drawing attention after traders cited a Northland upgrade tied to its C3 Code agentic-AI platform, alongside heavy call activity and the stocks potential as a short-squeeze candidate. Bullish traders see a turnaround opportunity, while skeptics point to declining revenue and persistent losses as reasons for caution.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave shares are drawing attention amid a steep selloff across quantum-computing stocks, with traders questioning whether high valuations, limited near-term commercialization and competition from classical AI can support the sector ahead of Q3 results. Some see the pullback as a buying opportunity, while others expect more downside.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, led by Dupixent and Eylea HD, drove a sharp share-price jump and a fresh high. Traders largely welcomed the report, while debating whether the breakout can hold and pointing to heavy call-option activity.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

Discussion centers on REalloys speculative role in a North American rare-earth and magnet supply chain ahead of 2027 U.S. defense sourcing restrictions, including its Army-linked Tooele opportunity and Tanbreez offtake agreement. Bulls point to strategic demand and potential sector momentum, while skeptics cite limited company updates, execution risk and sharp volatility; the Tooele discussions are not presented as a finalized agreement.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLAs quarterly results topped expectations and its forward outlook was strong, but shares are falling amid weakness in tech and semiconductor equipment stocks. Traders are debating whether the selloff reflects sector-wide risk-off and valuation pressure, or an overreaction to solid fundamentals; analyst price-target cuts have added to the discussion.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

BLZE is under pressure after a steep pullback, with traders pointing to broader tech weakness and CoreWeaves decline while positioning around the upcoming earnings report. The community is split between dip-buyers betting on strong results or new contracts and cautious traders concerned that earnings could bring further losses.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is falling amid a broad semiconductor selloff that traders attribute largely to Intels weak forward guidance, with some also pointing to bearish put-option activity. The community is split between buying the pullback and expecting further downside, while noting the drop appears tied more to sector pressure than a clear Qualcomm-specific catalyst.

BitGo Holdings, Inc. operates as a digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. It focuses on accelerating the transition of the financial system to a digital asset economy. The company was founded by Michael Belshe and Ben Davenport in 2013 and is headquartered in Sioux Falls, SD.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGos latest earnings are drawing attention: traders are weighing strong revenue growth against a wider net loss, with some blaming the results for renewed share-price weakness. Bullish investors argue that Bitcoins recovery and expanding custody and institutional services could support a rebound, while others remain concerned about profitability and the stocks persistent decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million.
Propanc Biopharma (NASDAQ:PPCB) stock increased byread more...

Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings

U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma soared 157%. Okta and Veeva Systems also rose. Build-A-Bear Workshop and Healthequity fell on earnings...

Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.read more...

Mega Movers

The market is getting a fresh reminder that the biggest opportunities are increasingly being built around AI, cybersecurity, advanced medicine and the infrastructure required to commercialize them. Propanc Biopharma (NASDAQ:PPCB), Celularity (NASDAQ:CELU), NeOnc Technologies (NASDAQ:NTHI), Salesforce (NYSE:CRM), CrowdStrike (NASDAQ:CRWD), and Okta (NASDAQ:OKTA).

Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results

US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings. Propanc Biopharma up 211%, VolitionRX up 86%, Mint Incorporation up 74%, Alpha Modus down 25%, Change...

Propanc’s PRP Just Entered a New Cancer Conversation

Propanc Biopharma (NASDAQ:PPCB) is moving into a potentially important moment for its lead cancer candidate PRP, as new preclinical data arrive just as the pancreatic-cancer treatment landscape is undergoing a major transformation.

PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally?

Equity

Propanc Biopharma announced the approval of a share buyback program worth up to $5 million.

Clinical-Stage Biotech Rockets 308% After $5M Buyback and Phase 1 Cancer-Trial Path

For early-stage life sciences plays, deploying capital into a buyback program serves to validate management's view of a company's pipeline value. Today, an international developer focused on treating metastatic solid-tumor cancers triggered a triple-digit single-session market rally following a dual operational and capital-allocation update.
Propanc Biopharma, Inc. (Nasdaq: PPCB) surged in Wednesday trading announcing its board of directors approved a $5.0M common-stock repurchase program. Management explicitly framed the capital-return initiative alongside core execution milestones for ...

Biotech And AI Stocks Deliver Fresh Catalysts, as Investors Swarm into Growth Stories

Today's market action highlighted a familiar theme across the small-cap landscape: investors continue searching for transformative growth stories amid a market increasingly driven by company-specific catalysts. $TGNT, $TOVX, $MGNI, $PPCB, $MASK

This account has been verified as an official PPCB representative.

Verified Account

Propanc Biopharma Responder

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

Propanc Biopharma Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The management said the current stock price does not fully reflect the company’s underlying value and long-term potential.</li><li>Propanc had implemented a 1-for-25 reverse stock split on May 18.</li><li>The biotech firm is currently working on two cancer research programs.</li></ul>Shares of Propanc Biopharma (PPCB) ripped past 200% on Thursday, clocking their biggest single-day gains since the company implemented a reverse stock split last month, as investors cheered a share repurchase program that authorizes it to buy back up to $5 million of its common stock.At the time of writing, the company’s market cap was around $4 million.The biotech firm said it may repurchase shares from time to time, citing its belief that the current stock price does not fully reflect the company’s underlying value and long-term potential.“Repurchases will be considered when we believe the market price meaningfully understates intrinsic value and when buybacks compete favorably relative to other uses of capital. We believe we are approaching such a position,” said James Nathanielsz, Propanc’s chief executive officer.<h2 class="st-heading-2">PPCB’s Reverse Stock Split Took Effect On May 18</h2>The latest development comes less than a month after Propanc implemented a 1-for-25 reverse stock split. As a result, the company's outstanding share count was reduced from about 57 million to roughly 2.3 million.The reverse stock split was implemented to restore compliance with Nasdaq’s $1 minimum bid price requirement and to support growth plans, Nathanielsz said.<h2 class="st-heading-2">What’s In PPCB’s Pipeline?</h2>Propanc Biopharma is working on two cancer research programs. Earlier this year, it partnered with Germany-based FyoniBio to develop and validate a pharmacokinetics assay for its Phase 1b first-in-human study of its lead cancer therapy candidate. The assay will help measure drug levels and activity in patients with advanced solid tumors.Separately, Propanc entered into a multi-year research collaboration with the Universities of Jaén and Granada in Spain to evaluate an anti-aging compound and conduct additional studies to support the company’s fibrosis- and cancer-related patent applications.<h2 class="st-heading-2">Retail’s Take On PPCB’s Super Rally</h2>Retail sentiment surrounding <a href="https://stocktwits.com/symbol/PPCB">PPCB</a> on Stocktwits turned ‘extremely bullish’ from ‘neutral,’ amid ‘extremely high’ message volumes.One user said the stock’s momentum could last for a couple of days and expects support at around $4.<stembedurl>https://stocktwits.com/DeltaVariant/message/656140841</stembedurl>However, another user called it a “high-risk bet on short-term retail momentum.”<stembedurl>https://stocktwits.com/Zipcash/message/656137996</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/equity/markets/iran-targets-elon-musk-companies-spacex-in-focus/cZKTuuJR720">SpaceX Assets Among Iran’s Military Targets, Says State Media – Accuses Elon Musk-Related Businesses Of Supporting ‘War Crimes’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.84
Prev Close	$2.11
Open	$1.91
Dividend Yield	0.00%
50-Day Moving Average	$6.72
Beta	0.00
Avg. Volume	32,183.76
PE Ratio	-0.01

52-Week High	$315.00
52-Week Low	$1.79
Market Capitalization	$1.9M
EPS (Annual)	-$176.16
Price to Book	0.06
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

PPCB Fundamentals